The results of the current study are consistent with this previous research, further demonstrating that AMI alleviates pulmonary fibrosis in mice by inhibiting BLM-induced oxidative stress, inflammation, and apoptosis and by reducing EMT and ECM aggregation through inhibition of the PI3K/Akt/mTOR signaling pathway. The gene discussed is MTOR; the disease is pulmonary fibrosis.